SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

News in brief

DEA licenses Pharmatek for controlled substance analysis

18-Apr-2011

Pharmatek Laboratories has received US DEA approval for the analysis of Schedule I to IV controlled substances.

The US Drug Enforcement Agency (DEA) license allows Pharmatek to perform analytical and stability testing of controlled-substance drug products in its non-potent and highly-potent plants. Pharmatek already had a license to develop and manufacture Schedule IV and V products.

 

"Receipt of this additional registration from the DEA…further validates our facility design, security systems, and procedures for analysis, handling, storage and disposal of controlled substances", said Jeffrey Bibbs, CEO and chief scientific officer at Pharmatek.

Key Industry Events

 

Access all events listing

Our events, Events from partners...

On demand Supplier Webinars

A brief history of bioavailability
William Reed Business Media
Bioavailability market dynamics
William Reed Business Media
All supplier webinars